1
|
Marzhoseyni Z, Shojaie L, Tabatabaei SA, Movahedpour A, Safari M, Esmaeili D, Mahjoubin-Tehran M, Jalili A, Morshedi K, Khan H, Okhravi R, Hamblin MR, Mirzaei H. Streptococcal bacterial components in cancer therapy. Cancer Gene Ther 2022; 29:141-155. [PMID: 33753868 DOI: 10.1038/s41417-021-00308-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 01/25/2021] [Accepted: 02/05/2021] [Indexed: 02/01/2023]
Abstract
The incidence rate of cancer is steadily increasing all around the world, and there is an urgent need to develop novel and more effective treatment strategies. Recently, bacterial therapy has been investigated as a new approach to target cancer, and is becoming a serious option. Streptococcus strains are among the most common and well-studied virulent bacteria that cause a variety of human infections. Everyone has experienced a sore throat during their lifetime, or has been asymptomatically colonized by streptococci. The ability of Streptococcus bacteria to fight cancer was discovered more than 100 years ago, and over the years has undergone clinical trials, but the mechanism is not yet completely understood. Recently, several animal models and human clinical trials have been reported. Streptococcal strains can have an intrinsic anti-tumor activity, or can activate the host immune system to fight the tumor. Bacteria can selectively accumulate and proliferate in the hypoxic regions of solid tumors. Moreover, the bacteria can be genetically engineered to secrete toxins or enzymes that can specifically attack the tumors.
Collapse
Affiliation(s)
- Zeynab Marzhoseyni
- Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Layla Shojaie
- Research Center for Liver Diseases, Keck School of Medicine, Department of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Seyed Alireza Tabatabaei
- Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
| | - Ahmad Movahedpour
- Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mahmood Safari
- Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Davoud Esmaeili
- Department of Microbiology and Applied Microbiology Research Center, Systems Biology and Poisonings Institute and Department of Microbiology, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Maryam Mahjoubin-Tehran
- Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amin Jalili
- Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Korosh Morshedi
- School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Haroon Khan
- Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan
| | - Ranaa Okhravi
- Department of Medical Sciences, Shahrood Branch, Islamic Azad University, Shahrood, Iran.
| | - Michael R Hamblin
- Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa.
| | - Hamed Mirzaei
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
| |
Collapse
|
2
|
Kramskaya T, Leontieva G, Desheva Y, Grabovskaya K, Gupalova T, Rudenko L, Suvorov A. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice. PLoS One 2019; 14:e0222148. [PMID: 31513620 PMCID: PMC6742370 DOI: 10.1371/journal.pone.0222148] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Accepted: 08/22/2019] [Indexed: 11/29/2022] Open
Abstract
Influenza and its bacterial complications are a leading cause of morbidity and mortality worldwide. The effect of combined immunization with live influenza vaccine and recombinant chimeric pneumococcal protein in dual infection caused by influenza H1N1 and S. pneumoniae (serotype 3) has been studied. The combined vaccine consisted of the strain A/California/2009/38 (H1N1) pdm and chimeric recombinant protein PSPF composed of immunodominant fragments of the surface virulence factors of S. pneumoniae—PsaA, PspA, and Shr1875—associated with modified salmonella flagellin. Vaccinated mice were infected with the influenza virus 24 hours before or 24 hours after the onset of pneumococcal infection. The protective effect of combined vaccination was shown on both models of viral-bacterial infection.
Collapse
Affiliation(s)
- T. Kramskaya
- Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
| | - G. Leontieva
- Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
- * E-mail:
| | - Yu. Desheva
- Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
- Department of Fundamental Medicine and Medical Technologies, Faculty of Dentistry and Medical Technologies, Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - K. Grabovskaya
- Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
| | - T. Gupalova
- Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
| | - L. Rudenko
- Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
| | - A. Suvorov
- Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation
- Department of Fundamental Medicine and Medical Technologies, Faculty of Dentistry and Medical Technologies, Saint Petersburg State University, Saint Petersburg, Russian Federation
| |
Collapse
|
3
|
Desheva YA, Leontieva GF, Kramskaya TA, Landgraf GO, Sychev IA, Rekstin AR, Suvorov AN. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection. Heliyon 2019; 5:e01154. [PMID: 30839941 PMCID: PMC6365543 DOI: 10.1016/j.heliyon.2019.e01154] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 08/21/2018] [Accepted: 01/18/2019] [Indexed: 12/29/2022] Open
Abstract
We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.
Collapse
Affiliation(s)
- Yulia A Desheva
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation.,Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Galina F Leontieva
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation
| | - Tatiana A Kramskaya
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation
| | - Galina O Landgraf
- Saint Petersburg State University, Saint Petersburg, Russian Federation
| | - Ivan A Sychev
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation
| | - Andrey R Rekstin
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation
| | - Alexander N Suvorov
- Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Saint Petersburg, Acad. Pavlov's Str., 12, 197376, Russian Federation.,Saint Petersburg State University, Saint Petersburg, Russian Federation
| |
Collapse
|
4
|
Gupalova T, Leontieva G, Kramskaya T, Grabovskaya K, Bormotova E, Korjevski D, Suvorov A. Development of experimental GBS vaccine for mucosal immunization. PLoS One 2018; 13:e0196564. [PMID: 29727446 PMCID: PMC5935385 DOI: 10.1371/journal.pone.0196564] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Accepted: 04/16/2018] [Indexed: 12/17/2022] Open
Abstract
Streptococcus agalactiae, or group B streptococcus (GBS), is an important pathogen as it is the leading cause of neonatal deaths due to sepsis, meningitis or bacterial pneumonia. Although the development of an effective and safe GBS vaccine is on the agenda of many research labs, there is no GBS vaccine on the market yet. In the present study we attempted to engineer a live vaccine strain based on Bac, a surface protein of GBS, incorporated into a surface fimbrial protein of probiotic Enterococcus. The resulting strain induced specific systemic and local immune responses in mice and provided protection against GBS when administered via the intranasal, oral or intravaginal immunization routes.
Collapse
MESH Headings
- Administration, Intranasal
- Administration, Intravaginal
- Administration, Oral
- Animals
- Antibodies, Bacterial/biosynthesis
- Antibodies, Bacterial/blood
- Bacterial Load
- Bacterial Proteins/genetics
- Bacterial Proteins/immunology
- Enterococcus faecium/genetics
- Enterococcus faecium/immunology
- Female
- Fimbriae Proteins/genetics
- Fimbriae Proteins/immunology
- Immunity, Mucosal
- Mice
- Probiotics
- Streptococcal Infections/immunology
- Streptococcal Infections/microbiology
- Streptococcal Infections/prevention & control
- Streptococcal Vaccines/administration & dosage
- Streptococcal Vaccines/genetics
- Streptococcal Vaccines/immunology
- Streptococcus agalactiae/genetics
- Streptococcus agalactiae/immunology
- Streptococcus agalactiae/pathogenicity
- Vaccines, Conjugate/administration & dosage
- Vaccines, Conjugate/genetics
- Vaccines, Conjugate/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- T. Gupalova
- Institute of Experimental Medicine, Saint-Petersburg, Russia
| | - G. Leontieva
- Institute of Experimental Medicine, Saint-Petersburg, Russia
- * E-mail:
| | - T. Kramskaya
- Institute of Experimental Medicine, Saint-Petersburg, Russia
| | - K. Grabovskaya
- Institute of Experimental Medicine, Saint-Petersburg, Russia
| | - E. Bormotova
- Institute of Experimental Medicine, Saint-Petersburg, Russia
| | - D. Korjevski
- Institute of Experimental Medicine, Saint-Petersburg, Russia
| | - A. Suvorov
- Institute of Experimental Medicine, Saint-Petersburg, Russia
- Saint Petersburg State University, Saint-Petersburg, Russia
| |
Collapse
|